About Our Practice

This research study will collect data to demonstrate safety and effectiveness of the Volt Pulsed Field Ablation (PFA) System for the treatment of Atrial Fibrillation (AF). It will enroll patients who are scheduled to undergo an ablation for treatment of AF. The Volt PFA System is an investigational device. This means that it is not approved by the Food and Drug Administration (FDA) to treat AF.

This study is currently in follow-up only and is not enrolling new patients

The purpose of this research is to evaluate the safety and effectiveness of the Adagio Medical vCLAS™Cryoablation System (Adagio System) for the treatment of a heart arrhythmia called Ventricular Tachycardia (VT). It is enrolling patients who are scheduled to undergo cardiac ablation to treat the VT. While the FDA has approved the clinical use of this device in a pre-market investigational device exemption (IDE) study, the device has not been approved by the FDA for commercial use in the US.

The purpose of this study is to determine the accuracy of monitoring heart rate and respiratory (breathing) rate measured by the Cardi/o ATX-2410 device in patients seeing a doctor in a clinical setting. Cardi/o is a contactless, wireless, radar-based sensing monitor for heart rate, and respiratory rate within approximately 3 meters of the device using Wi-Fi. The device passively monitors a patient and transmits information, including continuous heart and respiratory rate and alerts to a healthcare professional’s workstation or phone-based application. 

AtriCure’s ISOLATOR® Synergy Surgical Ablation System has been cleared under the 510(k) process by the United States Food and Drug Administration (FDA) to ablate the heart to treat cardiac arrhythmias in patients undergoing open heart surgery. It is currently in commercial use in the US and various European countries however for the purposes of this trial will be labeled for Investigational Use Only.

This study will enroll patients who have been diagnosed with symptomatic Paroxysmal Atrial Fibrillation (PAF) and have decided to undergo cardiac ablation. The purpose of this research study is to provide information about the safety and long-term effectiveness of the BWI OMNYPULSE™ Pulsed Field Ablation (PFA) Platform, consisting of the TRUPULSE™ Generator and OMNYPULSE™ Catheter used in conjunction with the CARTO®3 System with the VISITAG SURPOINT™Module PF Index to treat symptomatic PAF. The BWI OMNYPULSE™ PFA Platform is an investigational device that has not been approved by the FDA.

The BWI PF/RF Ablation system is an investigational device that has not been approved by the US Food and Drug Administration (FDA) for the treatment of PAF.

This study is being conducted toe valuate whether a new treatment called the FARAPULSE Pulsed Field Ablation System is safe and works well for people with symptoms of persistent atrial fibrillation (PsAF). The treatment uses a type of electricity that comes in short bursts. This system is made by Boston Scientific Corporation, who is also the sponsor of this research study. The study will enroll patients who have PsAF and are scheduled to undergo a cardiac ablation.

For the Phase II of this study, a specific Insertable Cardiac Monitor (ICM) called LUX-Dx will be inserted if you do not already have one with adequate battery life. It will be used for the detection of abnormal heart rhythms and long-term monitoring.

The FARAPULSE Pulsed Field Ablation System is considered investigational because it is not approved by the Food and Drug Administration (FDA) for use within the United States for the treatment of PsAF.

This study is currently in follow-up only and is not enrolling new patients.

This trial will compare ablation using the FARAPULSED™ Pulsed Field Ablation (PFA) system vs anti-arrhythmic drug (AAD) therapy as the initial therapy for persistent AF treatment. PFA procedures are done with electrical energy emitted by pulses and are still considered investigational and not yet approved by the Food and Drug Administration (FDA) as an initial treatment for Persistent AF. 

The primary objective of this randomized study is to determine if LAA closure with the Watchman FLX device is a reasonable alternative to non-vitamin K oral anticoagulants (NOACs). The Watchman FLX device has been approved by the FDA but is considered investigational for this study.

This study is currently in follow-up only and is not enrolling new patients.

This study will enroll patients who have been implanted or will be implanted with a WATCHMAN  FLX™ Pro Device. The WATCHMAN FLX™ Pro device is approved for commercial use in the United States and is a newly FDA approved version of the previous device called WATCHMAN  FLX™ Device.

This study is observational and will collect and analyze clinical information on patients who receive the WATCHMAN  FLX™ Pro device

This study is currently in follow-up only and is not enrolling new patients

This is a registry for patients undergoing an ablation using the FDA approved Farapulse system. The purpose of this Registry is to learn more about the outcomes for patients who receive an ablation using the Farapulse™ Pulsed Field Ablation System for the treatment for Paroxysmal Atrial Fibrillation (PAF), Persistent (PsAF) Atrial Fibrillation, and Long-Standing Persistent Atrial Fibrillation (LSPsAF).

The purpose of this post-approval study (PAS) is to evaluate the safety of long-term use of the OPTIMIZER Smart and CCM therapy. The study will also evaluate the effects of CCM therapy on your quality of life and HF symptoms.

The purpose of this research study is to create a prospective registry of patients with a history of GI bleeding who are having a WATCHMAN-FLX device implanted. Patients will receive standard care during the implant and on subsequent follow up visits. Medical records will be collected by study staff throughout participation to assess the success of the implant procedure and assess health status after implantation.

This study will enroll patients who are scheduled to receive a left atrial appendage (LAA) closure device. The purpose of this research study is to compare the safety and effectiveness of the Laminar LAA Closure System as compared to a commercially available LAA closure device to close off the LAA to eliminate a potential source of blood clots. The study will be randomized into one of two groups by a computer. The device is experimental, which means it has not been approved by the Food and Drug Administration (FDA) for commercial sale.

Participants in this study are scheduled to have a cryoablation procedure using the Medtronic Arctic Front™ System or Freezor™MAX Family of Cardiac Cryoablation Catheters (Arctic Front™) for the treatment of your persistent atrial fibrillation (AF). This type of procedure targets cardiac tissue that is causing your AF in order to freeze and destroy the abnormal tissue. The purpose of this study is to describe clinical performance and safety data in persistent AF patients treated with the Arctic Front™ and Freezor™MAX Families of Cardiac Cryoablation Catheters, which are approved by the U.S. Food and Drug Administration (FDA).

This study is currently in follow-up only and is not enrolling new patients.

The purpose of this study is to provide information about the safety and long-term effectiveness of the BWI (Biosense Webster) irreversible electroporation (IRE) ablation system consisting of the TRUPULSE™Generator and VARIPULSE™Catheter. It will enroll patients who are scheduled to undergo an atrial fibrillation (AF) ablation to treat AF. 

The BWI IRE Ablation system uses a new type of energy source called pulsed field, which uses ultra-rapid electrical fields on the heart muscle to cause IRE to treat AF. The system is investigational and has not been approved by the Food and Drug Administration (FDA). 

The purpose of this research study is to answer specific questions about the accuracy of an artificial intelligence (AI) Software as Medical Device (SaMD) which is intended to compute ejection fraction (EF) severity from ambulatory ECG wearable patch (a patch to be used while walking around). The AI software is used to process previously acquired continuous ECG data produced by the FDA cleared Peerbridge Cor® ECG Wearable Monitor to aid in screening for left ventricle EF severity classification. 

The Peerbridge COR® ECG wearable devices that are being used in this study have been cleared by the United States Food and Drug Administration (FDA). However, the use of the device to estimate EF is considered investigational.

This study will enroll patients with atrial fibrillation (AF). This condition can decrease the heart’s pumping capacity, which can form clots in the left atrial appendage (LAA) which can escape and lead to stroke. The purpose of the LAAOS-4 study is to determine if closure of the LAA using a closure device called the WATCHMAN™, in addition to taking oral anticoagulant medications (OAC), is more effective at reducing strokes and blood clots than taking OAC medications on their own.

The purpose of this study is to evaluate the impact of anxiety on the heart tissue changes leading to non-PV triggers and LA scar in patients after AF ablation.

This study will enroll patients who have had or will be undergoing a left atrial appendage occlusion (LAAO) procedure. A rare but known complication is the development of a clot on the LAAO device. This study will evaluate blood samples to identify blood protein biomarkers that could predict clot formation. The purpose of this study is to examine the association of blood-proteins with LAAO-related clot. 

The purpose of this research is to test the safety of the investigational Biosense Webster Inc (BWI) IRE (irreversible electroporation) Ablation system for people with symptomatic atrial fibrillation (AF). This system uses voltage generated by the TRUPULSE™ Generator when connected to the VARIPULSE™ Catheter using a new type of energy source called pulse field.  It will enroll patients who are undergoing ablation procedure to treat either Paroxysmal AF (PAF) or persistent AF (PerAF). 

This system is investigational and has not been approved by the U.S. FDA for commercial use but has been approved for use during this study

This study will enroll patients who are scheduled to undergo pulsed-field ablation (PFA) procedure to treat persistent AF (PerAF). Pulse field ablation applies ultra-rapid (less than1 second) electrical fields to the heart muscle to cause irreversible electroporation (IRE) to treat AF. This system has been approved in the Europe and by the U.S. Food & Drug Administration (FDA).

Study-participants will be randomly assigned to either pulmonary vein isolation (PVI) + Vein of Marshall (VoM) ablation or PVI+ isolation of left atrial posterior wall (PWI). This study is designed to directly compare the safety and efficacy of PFA-based PVI+PWI vs PFA-based PVI+ VoM alcohol ablation in patients with PersAF.